Product Reports Resources Pricing Login Book a demo

Xenon Pharmaceuticals

Biotech & Life Sciences · Burnaby, Canada · Founded 1996 · IPO 2014

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address neurological disorders. The company operates primarily in the healthcare and pharmaceutical markets, targeting conditions such as epilepsy and other central nervous system disorders. Xenon's business model revolves around the research, development, and commercialization of novel therapies. Revenue is generated through partnerships, licensing agreements, and potential future product sales. The company serves a diverse client base, including healthcare providers, patients, and research institutions. Xenon leverages its expertise in genetics and neurology to create a robust pipeline of drug candidates, currently highlighted by its Phase 2 proof of concept study for XEN007 in pediatric patients with treatment-resistant childhood absence epilepsy (CAE). The company's strategic focus on unmet medical needs and its commitment to advancing neurology therapies position it as a key player in the biopharmaceutical industry. Keywords: neurology, epilepsy, therapeutics, clinical-stage, biopharmaceutical, genetics, CNS disorders, drug development, healthcare, innovation.

Valuation $4.97B
Revenue $7.5M
Total funding $50–100M
Power Law Unicorn$1–10B valuation tier

Investors

9 investors on Xenon Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage
InterWest Partners
GrowthWorks Capital
Novo Ventures
RBC Venture Partners
JP Morgan
Invesco Private Capital
Takeda
Series B+ 2 investors entered at this stage
Northview LifeSciences
Neurocrine Biosciences

Global footprint

Where Xenon Pharmaceuticals has talent and traffic

Workforce by country
6 countries with
team presence
🇺🇸 United States49.2%
🇨🇦 Canada48.5%
🇵🇰 Pakistan1.3%
🇦🇺 Australia0.3%
🇰🇷 South Korea0.3%
Top 5 of 6 shown
Web traffic by country
23K monthly visits
across markets
🇺🇸 United States54.3%
🇨🇦 Canada25.2%
🇬🇧 United Kingdom7%
🇵🇭 Philippines4.3%
🇮🇳 India3.5%
Top 5 markets shown

Talent graph

The shape of Xenon Pharmaceuticals's talent

Dealroom maps Xenon Pharmaceuticals's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

16 team members profilednamed & role-tagged by Dealroom
415 employeestotal headcount
6 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Xenon Pharmaceuticals's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$90M patent portfolio · 68 active families

Estimated portfolio value
$90M
1.8% of market cap · comparable to top peer Souzhou Ribo Life Science ($63M)
68 active patent families
Where Xenon Pharmaceuticals innovates DiseaseDisease injuryEnantiomerPharmaceutical SubstancesPharmaceutical medicine

Where Xenon Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Xenon Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Xenon Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Xenon Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xenon Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles